ID   MP2K5_RAT               Reviewed;         448 AA.
AC   Q62862; Q62863; Q62864;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   02-OCT-2024, entry version 185.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 5;
DE            Short=MAP kinase kinase 5;
DE            Short=MAPKK 5;
DE            EC=2.7.12.2;
DE   AltName: Full=MAPK/ERK kinase 5;
DE            Short=MEK 5;
GN   Name=Map2k5; Synonyms=Mek5, Mkk5, Prkmk5;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA-1; ALPHA-2 AND BETA), FUNCTION,
RP   TISSUE SPECIFICITY (ISOFORMS ALPHA-1: ALPHA-2 AND BETA), AND MUTAGENESIS OF
RP   SER-311 AND THR-315.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=7499418; DOI=10.1074/jbc.270.48.28897;
RA   English J.M., Vanderbilt C.A., Xu S., Marcus S., Cobb M.H.;
RT   "Isolation of MEK5 and differential expression of alternatively spliced
RT   forms.";
RL   J. Biol. Chem. 270:28897-28902(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION.
RX   PubMed=20724525; DOI=10.1096/fj.10-162636;
RA   Woo C.H., Le N.T., Shishido T., Chang E., Lee H., Heo K.S., Mickelsen D.M.,
RA   Lu Y., McClain C., Spangenberg T., Yan C., Molina C.A., Yang J.,
RA   Patterson C., Abe J.;
RT   "Novel role of C terminus of Hsc70-interacting protein (CHIP) ubiquitin
RT   ligase on inhibiting cardiac apoptosis and dysfunction via regulating ERK5-
RT   mediated degradation of inducible cAMP early repressor.";
RL   FASEB J. 24:4917-4928(2010).
CC   -!- FUNCTION: Acts as a scaffold for the formation of a ternary
CC       MAP3K2/MAP3K3-MAP3K5-MAPK7 signaling complex. Activation of this
CC       pathway appears to play a critical role in protecting cells from
CC       stress-induced apoptosis, neuronal survival and cardiac development and
CC       angiogenesis (By similarity). As part of the MAPK/ERK signaling
CC       pathway, acts as a negative regulator of apoptosis in cardiomyocytes
CC       via promotion of STUB1/CHIP-mediated ubiquitination and degradation of
CC       ICER-type isoforms of CREM (PubMed:20724525). {ECO:0000250,
CC       ECO:0000269|PubMed:20724525, ECO:0000269|PubMed:7499418}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.12.2;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.12.2;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- SUBUNIT: Interacts with PARD6A, MAP3K3 and MAPK7. Forms a complex with
CC       SQSTM1 and PRKCZ or PRKCI (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Isoform Beta]: Cytoplasm, cytosol.
CC   -!- SUBCELLULAR LOCATION: [Isoform Alpha-1]: Membrane. Note=The
CC       alternatively spliced exon in alpha isoform resemble conserved
CC       sequences that mediate interactions with the cytoskeleton, thereby
CC       explaining the differential localization.
CC   -!- SUBCELLULAR LOCATION: [Isoform Alpha-2]: Membrane. Note=The
CC       alternatively spliced exon in alpha isoform resemble conserved
CC       sequences that mediate interactions with the cytoskeleton, thereby
CC       explaining the differential localization.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Alpha-1;
CC         IsoId=Q62862-1; Sequence=Displayed;
CC       Name=Alpha-2;
CC         IsoId=Q62862-2; Sequence=VSP_004881;
CC       Name=Beta;
CC         IsoId=Q62862-3; Sequence=VSP_004880;
CC   -!- TISSUE SPECIFICITY: [Isoform Alpha-1]: Expressed in the liver and brain
CC       (at protein level). {ECO:0000269|PubMed:7499418}.
CC   -!- TISSUE SPECIFICITY: [Isoform Alpha-2]: Expressed in the liver and brain
CC       (at protein level). {ECO:0000269|PubMed:7499418}.
CC   -!- TISSUE SPECIFICITY: [Isoform Beta]: Expressed in the liver, muscle,
CC       testes, lung, kidney, spleen, heart and brain (at protein level).
CC       {ECO:0000269|PubMed:7499418}.
CC   -!- DOMAIN: Binds MAP3K2/MAP3K3 and MAPK7 via non-overlapping residues of
CC       the PB1 domain. This domain also mediates interactions with SQSTM1 and
CC       PARD6A (By similarity). {ECO:0000250}.
CC   -!- PTM: Activated by phosphorylation on Ser/Thr by MAP kinase kinase
CC       kinases. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U37462; AAC52320.1; -; mRNA.
DR   EMBL; U37463; AAC52321.1; -; mRNA.
DR   EMBL; U37464; AAC52322.1; -; mRNA.
DR   EMBL; BC078860; AAH78860.1; -; mRNA.
DR   RefSeq; NP_001029159.1; NM_001033987.1. [Q62862-1]
DR   RefSeq; NP_058942.1; NM_017246.2. [Q62862-2]
DR   RefSeq; XP_017450991.1; XM_017595502.1.
DR   AlphaFoldDB; Q62862; -.
DR   SMR; Q62862; -.
DR   IntAct; Q62862; 1.
DR   STRING; 10116.ENSRNOP00000050528; -.
DR   iPTMnet; Q62862; -.
DR   PhosphoSitePlus; Q62862; -.
DR   PaxDb; 10116-ENSRNOP00000050528; -.
DR   Ensembl; ENSRNOT00000010991.7; ENSRNOP00000010991.6; ENSRNOG00000007926.9. [Q62862-2]
DR   Ensembl; ENSRNOT00000051558.5; ENSRNOP00000050528.2; ENSRNOG00000007926.9. [Q62862-1]
DR   Ensembl; ENSRNOT00055044816; ENSRNOP00055036718; ENSRNOG00055025959. [Q62862-1]
DR   Ensembl; ENSRNOT00060036106; ENSRNOP00060029691; ENSRNOG00060020809. [Q62862-1]
DR   Ensembl; ENSRNOT00065012437; ENSRNOP00065009135; ENSRNOG00065007900. [Q62862-1]
DR   GeneID; 29568; -.
DR   KEGG; rno:29568; -.
DR   UCSC; RGD:61890; rat. [Q62862-1]
DR   AGR; RGD:61890; -.
DR   CTD; 5607; -.
DR   RGD; 61890; Map2k5.
DR   eggNOG; KOG0581; Eukaryota.
DR   GeneTree; ENSGT00940000157505; -.
DR   InParanoid; Q62862; -.
DR   OMA; ANDCTQV; -.
DR   OrthoDB; 2900742at2759; -.
DR   PhylomeDB; Q62862; -.
DR   BRENDA; 2.7.12.2; 5301.
DR   PRO; PR:Q62862; -.
DR   Proteomes; UP000002494; Chromosome 8.
DR   Bgee; ENSRNOG00000007926; Expressed in skeletal muscle tissue and 20 other cell types or tissues.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005819; C:spindle; ISO:RGD.
DR   GO; GO:0005524; F:ATP binding; IDA:RGD.
DR   GO; GO:0004707; F:MAP kinase activity; TAS:Reactome.
DR   GO; GO:0004708; F:MAP kinase kinase activity; ISO:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IDA:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IMP:BHF-UCL.
DR   GO; GO:0070375; P:ERK5 cascade; IMP:RGD.
DR   GO; GO:0007507; P:heart development; ISO:RGD.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; ISO:RGD.
DR   GO; GO:0000165; P:MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:2000342; P:negative regulation of chemokine (C-X-C motif) ligand 2 production; IMP:BHF-UCL.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:BHF-UCL.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:BHF-UCL.
DR   GO; GO:0034115; P:negative regulation of heterotypic cell-cell adhesion; IMP:BHF-UCL.
DR   GO; GO:0032717; P:negative regulation of interleukin-8 production; IMP:BHF-UCL.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IMP:BHF-UCL.
DR   GO; GO:0060761; P:negative regulation of response to cytokine stimulus; IMP:BHF-UCL.
DR   GO; GO:0034392; P:negative regulation of smooth muscle cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IMP:RGD.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:RGD.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IMP:BHF-UCL.
DR   GO; GO:0051247; P:positive regulation of protein metabolic process; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   CDD; cd06395; PB1_Map2k5; 1.
DR   CDD; cd06619; PKc_MKK5; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR053793; PB1-like.
DR   InterPro; IPR000270; PB1_dom.
DR   InterPro; IPR034851; PB1_MAP2K5.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR48013:SF26; DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 5; 1.
DR   PANTHER; PTHR48013; DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 5-RELATED; 1.
DR   Pfam; PF00564; PB1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00666; PB1; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF54277; CAD & PB1 domains; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS51745; PB1; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cytoplasm; Kinase; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Tyrosine-protein kinase.
FT   CHAIN           1..448
FT                   /note="Dual specificity mitogen-activated protein kinase
FT                   kinase 5"
FT                   /id="PRO_0000086385"
FT   DOMAIN          18..109
FT                   /note="PB1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01081"
FT   DOMAIN          166..419
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          18..25
FT                   /note="Interaction with MAPK7"
FT                   /evidence="ECO:0000250"
FT   REGION          64..68
FT                   /note="Interaction with MAP3K2/MAP3K3"
FT                   /evidence="ECO:0000250"
FT   REGION          116..144
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          117..131
FT                   /note="Interaction with MAPK7"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        123..144
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        283
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         172..180
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         195
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         311
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13163"
FT   MOD_RES         315
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13163"
FT   VAR_SEQ         1..89
FT                   /note="Missing (in isoform Beta)"
FT                   /evidence="ECO:0000303|PubMed:7499418"
FT                   /id="VSP_004880"
FT   VAR_SEQ         349..358
FT                   /note="Missing (in isoform Alpha-2)"
FT                   /evidence="ECO:0000303|PubMed:7499418"
FT                   /id="VSP_004881"
FT   MUTAGEN         311
FT                   /note="S->D: No change in activity."
FT                   /evidence="ECO:0000269|PubMed:7499418"
FT   MUTAGEN         315
FT                   /note="T->D: No change in activity."
FT                   /evidence="ECO:0000269|PubMed:7499418"
SQ   SEQUENCE   448 AA;  50198 MW;  1B1CC8B05789B90D CRC64;
     MLWLALGPFR AMENQVLVIR IKIPNSGAVD WTVHSGPQLL FRDVLDVIGQ VLPEATTTAF
     EYEDEDGDRI TVRSDEEMKA MLSYYYSTVM EQQVNGQLIE PLQIFPRACK PPGERNIHGL
     KVNTRAGPSQ HTSPVVSDSL PSNSLKKSSA ELRKILANGQ MNEQDIRYRD TLGHGNGGTV
     YKAYHVPSGK ILAVKVILLD ITLELQKQIM SELEILYKCD SSYIIGFYGA FFVENRISIC
     TEFMDGGSLD VYRKIPEHVL GRIAVAVVKG LTYLWSLKIL HRDVKPSNML VNTSGQVKLC
     DFGVSTQLVN SIAKTYVGTN AYMAPERISG EQYGIHSDVW SLGISFMELA LGRFPYPQIQ
     KNQGSLMPLQ LLQCIVDEDS PVLPLGEFSE PFVHFITQCM RKQPKERPAP EELMGHPFIV
     QFNDGNATVV SMWVCRALEE RRSQQGPP
//
